Advancing Human Disease Modeling and Precision Therapeutics

At FloBiotech, we develop advanced human brain cell models to unlock new therapeutic and diagnostic pathways for neurodegenerative diseases.
Explore Our Science
Contact Us
THE CHALLENGE

Why Alzheimer’s Disease (AD) treatment needs new approaches

Neurodegenerative diseases affect more than 55 million people worldwide and generate over $360B in annual healthcare costs, yet progress remains limited. Despite more than $42B invested across 200+ clinical trials, only modest clinical benefit has been achieved to date.

Key barriers remain:

Poor translation from animal models to humans

Over-focus on downstream pathology

Limited innovation in tau-driven disease biology

THE SOLUTION

Proprietary Platform for Disease Modeling & Precision Therapeutics

At FloBiotech, we are addressing neurodegeneration at its core to enable earlier risk reduction in drug development, improved translational success, and scalable pipeline expansion

FloCells™ Platform: human-relevant tauopathy modeling

Our proprietary platform is designed to replicate tau-driven neurodegenerative disease biology, overcoming the limitations of animal models

Key advantages:

  • Replicates human tau pathology in vitro
  • Identifies weak candidates pre-IND, reducing lates-stage attrition
  • Enables modeling of tauopathies previously inaccessible, including PSP
  • IP secured through patent filings covering platform applications

Clusterin Program: enhancing the brain’s natural defenscs

In partnership with a top-tier University, we are developing a precision therapy that supports the brain’s innate ability to manage au toxicity by enhancing soluble Clusterin

Clinical Significance:

  • Designed for early intervention in tau-driven neurodegeneration
  • Oral, brain-penetrant small molecule suitable for chronic administration
  • Precision-guided toward genetically fined patient populations
  • Potential to act across multiple disease-relevant pathways

Our Progress So Far

From early validation to expansion, milestones that mark our journey toward precision neurobiology

Proof-of-Concept Validation

Validated the FloCells™ Platform using human brain cell models replicating Alzheimer’s pathology.

Lab & Partnership Expansion

Forged collaborations with leading neuroscience institutes in France, Switzerland, and the UK.

Funding & Next-Stage Development

Secured European and private investment to scale FloCells™ and advance IND-enabling studies.

Follow our progress from discovery to development

Updates on our platform, progress, and milestones

Stay Informed